Calcium gluconate of the tab. of 500 mg No. 10

Translation of the instruction Mose

CALCIUM the GLUCONATE of a tablet of 500 mg

Instruction

On medical use of medicine

Ingredients:

Active ingredient: calcium gluconate.

1 tablet contains gluconate calcium in terms of 100% substance — 500 mg;

excipients: potato starch, sodium of a kroskarmeloz, talc, calcium stearate.

Dosage form.

Tablet.

Main physical and chemical properties: tablets of white color, ploskotsilindrichesky, with risky and a facet.

Pharmacotherapeutic group.

calcium Drugs. code atkh a12a a03.

Pharmacological properties.

Pharmacodynamics.

Calcium a gluconate — the calcic salt of gluconic acid containing 9% of calcium. Calcium ions participate in transfer of nervous impulses, reduction of unstriated and skeletal muscles, functioning of a myocardium, fibrillation processes; they are necessary for forming of a bone tissue, normal functioning of other systems and bodies. Concentration of calcium ions in blood decreases at many pathological processes; the expressed hypocalcemia promotes emergence of a tetany. Calcium the gluconate, except elimination of a hypocalcemia, reduces permeability of vessels, has antiallergic, anti-inflammatory, haemo static effect and also reduces exudation. Calcium ions are plastic material for a skeleton and teeth, participate in various enzymatic processes, regulate the speed of carrying out nervous impulses and permeability of cellular membranes. Calcium ions are necessary for neuromuscular transmission process, for maintenance of sokratitelny function of a myocardium. Unlike Calcii chloridum, calcium the gluconate has weaker local irritative effect.

Pharmacokinetics.

gluconate is partially soaked up by

At calcium intake, mainly — in a small intestine. The maximum concentration in blood plasma is reached in 1.2-1.3 hours. Elimination half-life of the ionized calcium makes 6.8-7.2 hours of blood plasma. Gets through a placental barrier and into breast milk. It is brought out of an organism with urine and a stake.

Clinical characteristics.

Indication.

Disease which are followed by a hypocalcemia, increase in permeability of cellular membranes, disturbance of carrying out nervous impulses in muscular fabric. a hypoparathyrosis (latent tetany, osteoporosis), vitamin D exchange disturbance (rickets, a spasmophilia, osteomalacy), a hyperphosphatemia at patients with chronic kidney disease. the increased need for calcium (the period of intensive growth at children and teenagers, pregnancy, the feeding period a breast), insufficient contents sa2 + in food, disturbance of its exchange in the post-menopausal period, bone fractures. removal strengthening sa2 + (a long bed rest, chronic diarrhea, a hypocalcemia at long intake of diuretics, antiepileptic medicines, glucocorticosteroids). in complex therapy: bleedings of a different etiology, allergic diseases (serum disease, small tortoiseshell, feverish syndrome, pruritic dermatosis, Quincke's disease); bronchial asthma, dystrophic alimentary hypostases, pulmonary tuberculosis, eclampsia, parenchymatous hepatitis, toxic damages of a liver, nephrite. poisoning with magnesium salts, oxalic acid, soluble salts of fluoric acid (in interaction from calcium are formed by a gluconate insoluble and non-toxic calcium oxalate and calcium fluoride).

Contraindication.

Hypersensitivity to medicament components, a hypercalcemia, the expressed hypercalcuria, hypercoagulation (the increased blood clotting), tendency to a thrombogenesis, the profound atherosclerosis, nefrourolitiaz (calcic), a heavy renal failure, a sarcoidosis, administration of medicaments of a foxglove.

Interaction with other medicines and other types of interactions.

Drug slows down absorption of estramustinum, the etidronat and other biphosphonates, hinolon, antibiotics of a tetracycline row, oral iron preparations and medicaments of fluorine (the interval between their reception has to be not less than 3 hours). calcium the gluconate reduces bioavailability of Phenytoinum. at a concomitant use with vitamin D or its derivatives the absorbability of calcium increases. holesterinamin reduces absorption of calcium in a digestive tract. at combined use of medicament with cardiac glycosides cardiotoxic effects of the last amplify. glucocorticosteroids reduce calcium absorption. at a combination to thiazide diuretics the risk of development of a hypercalcemia amplifies. medicament can reduce effect of calcitonin at a hypercalcemia, bioavailability of Phenytoinum, effect of blockers of calcium channels. at simultaneous use with quinidine the delay of intra ventricular conductivity and increase in toxicity of quinidine is possible.

Forms insoluble or slightly soluble salts of calcium with carbonates, salicylates, sulfates.

Absorption of calcium from digestive tract some types of food can reduce

(spinach, a rhubarb, bran, grain).

Feature of use.

At use to the patients receiving cardiac glycosides and/or diuretics and also at long-term treatment should control concentration of calcium and creatinine in blood. in case of increase in their concentration it is necessary to reduce a dose of medicament or to temporarily stop its use. because d3 vitamin increases absorption of calcium from digestive tract to avoid calcium overdose, it is necessary to consider intake of d3 vitamin and calcium from other sources.

to Patients with an insignificant hypercalcuria (more than 300 mg/days = 7.5 mmol/days), slightly profound renal failures, an urolithiasis in the anamnesis of calcium a gluconate it is necessary to appoint with care and to regularly control the level of excretion of calcium with urine. If necessary it is necessary to reduce a dose of medicament or to cancel it. Patients with tendency to formation of concrements in urinary tract during treatment are recommended to increase the volume of the consumed liquid.

At medicament treatment should avoid reception of high doses of vitamin D or its derivatives if only for this purpose there are no special indications.

Should observe an interval not less than 3 hours between reception of tablets of calcium of a gluconate and medicaments for oral administration of estramustinum, the etidronat and other biphosphonates, Phenytoinum, hinolon, antibiotics of a tetracycline row, oral iron preparations and medicaments of fluorine.

Use during pregnancy or feeding by a breast.

Use of medicament is admissible

taking into account a ratio advantage for woman/risk for a fruit (child) which is defined by the doctor. at use of medicaments of calcium during feeding by a breast its penetration into breast milk is possible.

Ability to influence speed of response at control of motor transport or other mechanisms.

Drug does not influence speed of response at control of motor transport and work with difficult mechanisms.

Route of administration and doses.

is Appointed inside before meal. the tablet needs to be chewed or crushed.

to Adults and children 14 years medicament are more senior than

appoint 1–3 g (2–6 tablets) in a single dose, children are from 3 to 4 years old — on 1 g (2 tablets), from 5 to 6 years — on 1-1.5 g (2–3 tablets), from 7 to 9 years — on 1.5-2 g (3–4 tablets), from 10 to 14 years — on 2–3 g (4–6 tablets) 2–3 times a day. The daily dose for patients of advanced age should not exceed 2 g (4 tablets) a day.

Duration of treatment is defined by the doctor individually, depending on a condition of the patient.

Children.

Drug is used to children aged from 3 years.

Overdose.

At prolonged use in high doses the hypercalcemia with adjournment of salts of calcium in an organism is possible

, the dispepsichesky phenomena are possible. the likelihood of development of a hypercalcemia raises at simultaneous treatment by high doses of vitamin D or its derivatives.

hypercalcemia Symptoms: drowsiness, weakness, anorexia, an abdominal pain, vomiting, nausea, a constipation, a polydipsia, a polyuria, increased fatigue, irritability, feeling sick, a depression, dehydration, are possible disturbances of a warm rhythm, myalgia, an arthralgia, arterial hypertension.

Treatment: medicament withdrawal; in hard cases — parenterally calcitonin in a dose of 5-10 ME/kg of body weight in day (divorced in 500 ml of sterile normal saline solution of sodium of chloride, intravenously by drop infusion within 6 hours. Perhaps intravenous jet slow administration 2–4 times a day).

Side reactions.

Drug is usually well transferred by

, but disturbances are sometimes possible:

from a digestive tract: nausea, vomiting, diarrhea, pain in epigastric area, constipations; at prolonged use in high doses — formation of calcic concrements in intestines;

from a cardiovascular system: bradycardia;

from a metabolism: hypercalcemia, hypercalcuria;

from an urinary system: renal failure (frequent urination, hypostases of the lower extremities).

emergence of allergic reactions Is possible

.

Specified phenomena quickly disappear after a dose decline or medicament withdrawal.

Expiration date.

8 years.

Storage conditions.

to Store to original packing at a temperature not over 25 º page

to Store out of children's reach.

Packing.

Tablet on 500 mg, No. 10 in a strip; No. 10 in the blister, 1 blister in a pack.

Category of release.

Without prescription.

Producer.

PJSC kiyevmedpreparat. PJSC galichfarm.

Location of the producer and address of the place of implementation of its activity.

PJSC kiyevmedpreparat, Ukraine, 01032, of cues, st. saksagansky, 139.

PJSC Galichfarm, Ukraine, 79024, Lviv, Opryshkovskaya St., 6/8.